Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

[1]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[2]  T. Choueiri,et al.  Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. , 2014, European urology.

[3]  J. Manola,et al.  PD10-04 LYMPHADENECTOMY AT THE TIME OF SURGERY FOR HIGH RISK LOCALIZED RCC: RESULTS FROM THE ASSURE ADJUVANT TRIAL (ECOG 2805) , 2014 .

[4]  T. Choueiri,et al.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.

[5]  T. Choueiri,et al.  Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.

[6]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[7]  J. Leppert,et al.  Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. , 2012, European urology.

[8]  M. Menon,et al.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[10]  J. Patard,et al.  Lymph node dissection in renal cell carcinoma. , 2011, European urology.

[11]  M. Meng,et al.  Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. , 2011, The Journal of urology.

[12]  M. Diederich,et al.  Anemia in cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Bensalah,et al.  Stage‐specific effect of nodal metastases on survival in patients with non‐metastatic renal cell carcinoma , 2009, BJU international.

[15]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Cheville,et al.  A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. , 2004, The Journal of urology.

[18]  R. Figlin,et al.  Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. , 2003, The Journal of urology.

[19]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  W. Linehan,et al.  Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. , 2001, The Journal of urology.

[21]  D. Jacqmin,et al.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.

[22]  U. Studer,et al.  Lymphadenectomy combined with radical nephrectomy: to do or not to do? , 2009, European urology.

[23]  B. Ljungberg.  Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881 , 2009 .